Compare GROV & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | TELA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | 295 | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 41.3M |
| IPO Year | N/A | 2019 |
| Metric | GROV | TELA |
|---|---|---|
| Price | $1.19 | $0.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.60 | ★ $2.00 |
| AVG Volume (30 Days) | 56.8K | ★ 85.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | $6.81 | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $1.03 | $0.50 |
| 52 Week High | $1.60 | $2.19 |
| Indicator | GROV | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 47.64 |
| Support Level | $1.10 | $0.79 |
| Resistance Level | $1.47 | $0.94 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 72.10 | 30.59 |
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.